# Aifred Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aifred-health

- Industry: Healthcare Specialists
- Headquarters: Montreal, Canada
- Website: www.aifredhealth.com
- Total disclosed funding: $4M
- Latest round: Seed (Dec 8, 2020)
- Investors on record: 4

## About

Aifred Health Inc. is a Montreal-based company specializing in AI-driven clinical decision support tools aimed at optimizing treatment for patients with major depression, enhancing the effectiveness of mental health care.Founded in 2016 in Montreal, Canada, Aifred Health Inc. focuses on developing AI technology to aid healthcare providers in treating mental health conditions. The company successfully secured CAD 5.12 million in Seed funding on December 8, 2020, co-led by MEDTEQ and BDC Capital, with involvement from Desjardins Capital and Highline BETA. The firm has completed 2 total deals and is lead by CEO Marina Massingham, while co-founders include Kelly Perlman and Robert Fratila.Aifred Health specializes in an AI-driven clinical decision support tool designed to optimize treatment selection for patients suffering from major depression. This product utilizes a sophisticated clinical algorithm that processes individual behavioral health data to provide physicians with precise insights regarding a patient's position within the disease cycle and recommendations for subsequent treatment steps, such as medication adjustments or the addition of psychotherapy. Launched following a successful multi-site clinical trial, the tool is currently accessible on any device, thereby supporting both telehealth and in-person consultations. Aifred Health primarily serves healthcare providers, including psychiatrists and general practitioners, in North America and is working towards regulatory approvals in the U.S. and Canada to formally commercialize its offerings. The end users of this technology are patients experiencing depression, with a particular focus on improving outcomes for those who have struggled with traditional trial-and-error medication methods.Aifred Health's revenue model is centered around the commercialization of its AI clinical decision support tool, which is structured to facilitate transactions directly with healthcare providers. The firm anticipates generating revenue through subscription-based partnerships with medical institutions and individual practitioners who utilize the tool to enhance their treatment protocols for depression. While specific pricing plans for these services are not disclosed, the model typically involves healthcare providers subscribing to access the AI technology, thereby integrating it into their clinical workflows. The company's flagship product, designed to assist in personalized treatment selection, has been validated through extensive clinical trials, positioning it as a pivotal solution for enhancing mental health care delivery in the U.S. and Canadian markets.Aifred Health plans to expand its product offerings, focusing on upcoming enhancements to its clinical decision support tool, although specific release dates are not provided. The company aims to penetrate further into the North American market while pursuing regulatory approvals in the U.S. and Canada to facilitate its commercial launch. The recent Seed funding of CAD 5.12 million will be instrumental in supporting these initiatives, ensuring Aifred Health can enhance its technology and broaden its market reach.

## Funding rounds

- Seed, Dec 8, 2020, $4M — BDC Capital, Desjardins Capital, Highline BETA, MEDTEQ+

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Seed
- Desjardins Capital (https://capitalatlas.ai/funds/desjardins-capital) — Seed
- Highline BETA (https://capitalatlas.ai/funds/highline-beta) — Seed
- MEDTEQ+ — Seed